Format

Send to

Choose Destination
Cancer Lett. 2013 Mar 1;330(1):57-66. doi: 10.1016/j.canlet.2012.11.020. Epub 2012 Nov 28.

Putative circulating markers of the early and advanced stages of breast cancer identified by high-resolution label-free proteomics.

Author information

1
Laboratório de Células Tronco, Instituto Nacional do Câncer, INCA, Rio de Janeiro, Brazil. carolpanis@sercomtel.com.br

Abstract

This study evaluated the plasmatic proteomic profile of breast cancer patients in the early (ED) and advanced (AD) stages, employing high-throughput proteomics. We identified 92 differentially expressed proteins in ED and 73 proteins in AD patients. Gelsolin, lumican, clusterin, SALL4 and PMS2, as well hTERT, TNF-α and GRHL3 were chosen for further investigation. ED presented augmented expression of GRHL3 and reduced circulating TNF-α with high expression of GRHL3 in tumors. AD displayed high TNF-α and a significant expression of PMS2 in tumors. These findings suggest processes enrolling stem cell division in ED, with TNF-α signaling and DNA mismatch repair in the advanced stage.

PMID:
23200674
DOI:
10.1016/j.canlet.2012.11.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center